Sectors
ORKA
Oruka Therapeutics, Inc.
95.38
2 x 71.53
2 x 126.45
bid
ask
+
0.42
0.44%
10:08 AM
timesize
| Ytd | 214.67% | |
| 1y | 513.34% |
94.35
day range
95.96
14.89
52 week range
115.52
| Open | 95.76 | Prev Close | 94.96 | Low | 94.35 | High | 95.96 | Mkt Cap | 6.30B |
| Vol | 116.68K | Avg Vol | 1.12M | EPS | -2.04 | P/E | N/A | Forward P/E | -33.18 |
| Beta | -0.34 | Short Ratio | 9.70 | Inst. Own | 116.59% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 96.29 | 200-d Avg | 61.11 | 1yr Est | 155.00 |
| Income Statement | |||
| Operating Expenses | 50.11M | ||
| Research and Development Expense | 43.26M | ||
| Selling, General and Administrative Expense | 6.85M | ||
| Operating Income | -50.11M | ||
| Net Income | -41.21M | ||
| Net Income Common Stock | -41.21M | ||
| Net Income Common Stock (USD) | -41.21M | ||
| Consolidated Income | -41.21M | ||
| Earnings per Basic Share | -0.55 | ||
| Earnings per Basic Share (USD) | -0.55 | ||
| Earnings per Diluted Share | -0.55 | ||
| Earning Before Interest & Taxes (EBIT) | -41.21M | ||
| Earning Before Interest & Taxes (USD) | -41.21M | ||
| Weighted Average Shares | 62.87M | ||
| Weighted Average Shares Diluted | 62.87M | ||
| Balance Sheet | |||
| Cash and Equivalents | 268.47M | ||
| Cash and Equivalents (USD) | 268.47M | ||
| Investments | 857.11M | ||
| Investments Current | 605.09M | ||
| Investments Non-Current | 252.02M | ||
| Current Assets | 884.56M | ||
| Property, Plant & Equipment Net | 2.69M | ||
| Total Assets | 1.14B | ||
| Debt Current | 669.00K | ||
| Total Debt | 2.55M | ||
| Current Liabilities | 22.97M | ||
| Debt Non-Current | 1.88M | ||
| Total Liabilities | 24.85M | ||
| Accumulated Retained Earnings (Deficit) | -262.18M | ||
| Accumulated Other Comprehensive Income | -1.70M | ||
| Shareholders Equity | 1.11B | ||
| Shareholders Equity (USD) | 1.11B | ||
| Assets Non-Current | 254.84M | ||
| Total Debt (USD) | 2.55M | ||
| Liabilities Non-Current | 1.88M | ||
| Trade and Non-Trade Payables | 7.95M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 192.00K | ||
| Net Cash Flow from Financing | 663.04M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 218.95M | ||
| Issuance (Purchase) of Equity Shares | 663.04M | ||
| Net Cash Flow from Investing | -410.95M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -410.95M | ||
| Net Cash Flow from Operations | -33.15M | ||
| Share Based Compensation | 7.28M | ||